Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
ISSN: 2471-9552
College of Life Sciences, Shihezi University, Xinjiang, China
Research Article
A Novel PD-L1 Nanobody Validates that Immune Cell Suppressed by Pd-L1 May Always Exist in the Body
Author(s): Chuangfu Chen*, Peng Wu and Jiao Jiao
Background: PD-L1 is expressed widely in the body. PD-1-PD-L1 interaction is known to drive T cell dysfunction,
which can be blocked by anti-PD-1/PD-L1 antibodies. Researchers have shown that blocking PD-L1 in both the
early and chronic stages of the disease may increase T cell activity. What’s more, we tried to find the improvement
of PD-L1 on the body's immunity.
Methods: Nanobody binding to PD-L1 was prepared, and the PD-L1 nanobody was verified by SDS-PAGE and
Western-Blot. Affinity detection of PD-L1 Nanobody and PD-L1 receptor was made by ELISA and flow cytometry.
The cytotoxicity of the PD-L1 nanobody was tested by BHK-21, MDBK, and sheep kidney cells. The inhibitory effect
on tumor model was verified. PD-L1 nanobody activated the macrophages was tested. Staphylococcus aureus was
used to test the prot.. View More»